Skip to main content
. 2021 Jan 7;16(1):27–35. doi: 10.1007/s11523-020-00784-0

Fig. 1.

Fig. 1

Progression-free survival (PFS) for the combined phase III and phase IV treatment-naïve sunitinib cohort versus the treatment-naïve placebo cohort in the phase III trial. CI confidence interval